Original Research

Analysis of Stakeholder Engagement in the Public Comments of ICER Draft Evidence Reports

Jean A. Gerlach; Brian Snow, PharmD; Katherine M. Prioli, MS; Ronald Vertsman, PharmD; Julie Patterson, PharmD, PhD; Laura T. Pizzi, PharmD, MPH

Business, Original Research

Knee Osteoarthritis Treatment Costs in the Medicare Patient Population

Gerard Malanga, MD; Faizan Niazi, PharmD; Vasco Deon Kidd, DHSc, MPH, MS, PA-C; Edmund Lau, MS; Steven M. Kurtz, PhD; Kevin L. Ong, PhD, PE; Andrew L. Concoff, MD, FACR, CAQSM

Clinical, Original Research

Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs for Patients with Newly Diagnosed Systolic versus Diastolic Heart Failure

Chi Nguyen, PhD; Xian Zhang, PhD; Thomas Evers, PhD; Vincent J. Willey, PharmD; Hiangkiat Tan, MS, BPharm; Thomas P. Power, MD, FACC, MRCPI

Business, Original Research

Budget Impact Analysis of a Home-Based Nutrition Program for Adults at Risk for Malnutrition

Suela Sulo, PhD, MSc; David Lanctin, MPH; Josh Feldstein, BA; Bjoern Schwander, MA, RN; Jamie Partridge, PhD, MBA; Wendy Landow, MPH; York F. Zöllner, MSc

Clinical, Original Research

A National Assessment of Diagnostic Test Use for Patients with Advanced NSCLC and Factors Influencing Physician Decision-Making

Madison M. Wempe, BS; Mark D. Stewart, PhD; Daniel Glass, PhD; Laura Lasiter, PhD; Diana Merino Vega, PhD; Nisha Ramamurthy; Jeff Allen, PhD; Ellen V. Sigal, PhD

Stakeholder Perspective

Navigating the Complex World of Diagnostic Tests and Their Role in Clinical Decision-Making

James T. Kenney, RPh, MBA

Clinical, Original Research

Mental Health Conditions and Hospitalizations for Ambulatory Care Sensitive Conditions Among Veterans with Diabetes

Drew A. Helmer, MD, MS; Nilanjana Dwibedi, BPharm, MBA, PhD; Mazhgan Rowneki, MPH; Chin-Lin Tseng, DrPH; Dennis Fried, PhD; Danielle Rose, PhD; Nisha Jani, MPH, PhD; Usha Sambamoorthi, PhD

Stakeholder Perspective

Mental Health Conditions Constitute Significant Comorbidity: The Impact on Potentially Avoidable Hospital Admissions

Gary M. Owens, MD

Business, Original Research

Expenditure, Utilization, and Cost of Specialty Drugs for Multiple Sclerosis in the US Medicaid Population, 2008-2018

Zizi Elsisi, BPharm; Ana L. Hincapie, PhD; Jeff Jianfei Guo, BPharm, PhD

Stakeholder Perspective

Utilization Challenges of Drugs for Multiple Sclerosis in a Medicaid Population

James T. Kenney, RPh, MBA

Business, Original Research

Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization

Allison Petrilla, MPH; Elizabeth Marrett, MPH; Xian Shen, PhD, MS, BS; Winghan Jacqueline Kwong, PharmD, PhD; Edmund Pezalla, MD, MPH

Stakeholder Perspective

Abuse-Deterrent Formulations of Prescription Opioids: A Missed Opportunity to Address the Current Opioid Crisis?

Atheer A. Kaddis, PharmD

Clinical, Original Research

Medication Use Before and After Hospitalization for Chronic Obstructive Pulmonary Disease in a Cohort of Elderly Patients with a Medicare Advantage Plan

Qingqing Xu, MS; Sarah S. Laxa, PharmD; Omar Serna, PharmD, BCACP; Sujit S. Sansgiry, MS, PhD

Stakeholder Perspective

Improving Medication Use for Chronic Diseases by Reducing Costs, Increasing Patient Adherence

F. Randy Vogenberg, PhD, FASHP

Clinical, Original Research

Real-World Dose Modification Patterns of Subcutaneous Tocilizumab Among Patients with Rheumatoid Arthritis

Rajeshwari Punekar, MPH, PhD; Jeannie Choi, PharmD; Susan Boklage, MS, MPH; Melitza Iglesias- Rodriguez, MD; Kamala Nola, PharmD, MS

Page 1 of 9
Results 1 - 10 of 83